[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transgenderism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transgenderism":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,51,77,107,127,151,175,196,217,242,277,299,321],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100546254","online-intervention-for-transgendernonbinary-young-adults-experiences-with-alcohol-and-romantic-relationships-100546254",false,"NCT06392542","Online Intervention for Transgender\u002FNonbinary Young Adults' Experiences With Alcohol and Romantic Relationships","Developing an Online Intervention Addressing Transgender\u002FNonbinary Young Adults' Experiences With Alcohol and Romantic Relationships","Inclusion Criteria:\n\n* Self-identify as transgender and\u002For nonbinary\n* Between 18 and 30 years of age, inclusive\n* Able to read and write in English\n* Residency in the United States\n* Currently in a romantic relationship that began at least six weeks prior to enrollment\n\nExclusion Criteria:\n\n* Prospective participants will be excluded as potentially inauthentic (i.e., not genuinely eligible for the study) based on scoring criteria developed through the investigators' prior online survey research with similar populations.","ALL","18 Years","30 Years",{"count":20,"type":21},107,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of this study is to learn more about Whole Selves, an interactive online resource (\"intervention\") to help transgender and\u002For nonbinary young adults reflect on their experiences and goals related to both alcohol use and romantic relationships. Existing online interventions focused on alcohol use often aren't a good fit for trans\u002Fnonbinary people, and existing relationship education programs don't account for how being trans\u002Fnonbinary might influence someone's relationships. For these reasons, the investigator is working with trans\u002Fnonbinary young adults and other community stakeholders to create a new intervention specifically for trans\u002Fnonbinary young adults. The goals of this clinical trial are to:\n\n1. Find out what transgender\u002Fnonbinary young adults think of the Whole Selves intervention in order to improve it\n2. See whether the Whole Selves intervention seems to work as expected\n3. Help the investigator make plans for a bigger clinical trial of the Whole Selves intervention, which could tell us how well it works\n\nIn this study, participants will use the Whole Selves intervention; complete online surveys about themselves, their romantic relationship experiences, their mental health, their alcohol use; and provide feedback on the Whole Selves intervention.",[27,28,29,30],"Alcohol Use, Unspecified","Relationship, Social","Depression, Anxiety","Transgenderism",[32,33,34,35,36,37],"Transgender young adults","Nonbinary young adults","Interactive online alcohol education","Interactive online relationship education","Whole Selves intervention","Supportive romantic relationships","NOT_YET_RECRUITING","2026-04-27",{"date":41,"type":42},"2026-04-28","ACTUAL",{"date":44,"type":21},"2026-07",{"date":46,"type":21},"2027-04",{"name":48,"class":49},"Boston University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":50},"100600056","phase-4-androgen-effects-on-the-reproductive-neuroendocrine-axis-2025-version-100600056","NCT07092527","Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version","Inclusion Criteria: Transgender\u002FNon-binary Group, Initiating Testosterone Group\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Aged 18-35\n* Plan to initiate testosterone therapy\n* History of regular menstrual cycles (every 24-35 days) at baseline, before beginning TRT\n\nInclusion Criteria: Cisgender Female Group\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Aged 18-35\n* Having regular menstrual cycles (every 24-35 days)\n\nExclusion Criteria: All\n\n* Pregnant\n* Incarcerated\n* Known cognitive impairment or institutionalized\n* Hemoglobin less than 11 gm\u002Fdl at screening evaluation\n* Weight less than 110 pounds\n* BMI \\\u003C18 or \\>35\n* Current endocrine disease- including untreated thyroid abnormalities, pituitary or adrenal disease, polycystic ovary syndrome, or androgen producing tumor\n* Current or recent pregnancy within two months of study enrollment\n* Current or recent breast feeding within two months of study enrollment\n* Diabetes, or renal, liver, or heart disease\n* History of oophorectomy or hysterectomy\n* History of radiation or surgery involving brain structures and\u002For pelvis\u002Fpelvic organs\n* Currently taking any medications that may affect their reproductive hormones, such as contraceptive medications, androgens, estrogens, progestins, gonadotropin-releasing hormone (GnRH) antagonists, insulinomimetics, and metformin.\n* History of prior testosterone therapy",true,"FEMALE","35 Years",{"count":61,"type":21},80,[63],"PHASE4","This research study investigates whether male-level exogenous androgens inhibit the reproductive neuroendocrine axis in otherwise healthy (non-PCOS) females.",[30,66],"Reproductive Issues","RECRUITING","2026-01-13",{"date":70,"type":42},"2026-01-15",{"date":72,"type":42},"2025-12-05",{"date":74,"type":21},"2028-11-30",{"name":76,"class":49},"University of California, San Diego",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":57,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":94,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":50},"100426841","effects-of-cross-sex-hormone-therapy-on-eating-behavior-metabolism-energy-balance-and-cardiovascular-system-100426841","NCT04838249","Effects of Cross-sex Hormone Therapy on Eating Behavior, Metabolism, Energy Balance and Cardiovascular System","Investigation of the Effects of Testosterone and Estrogen on Eating Behavior, Metabolism, Energy Balance and Cardiovascular System in Transsexual Patients Undergoing Cross-sex Hormone Therapy","HHS","Inclusion Criteria:\n\n* transsexual patients undergoing cross-sex hormone therapy versus controls\n* able to give informed consent, if \\\u003C18 years from all legal guardians\n* only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months, BMI ≤ 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* severe medical impairments (e.g., uncontrolled cardiovascular disease, severe heart failure, uncontrolled hypertension, cerebral insult, active malign disease, etc.)\n* self-initiated cross-sex hormone therapy before study start only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders (Cushing's disease, other uncontrolled pituitary disorders, uncontrolled hypothyroidism, hyperthyroidism, etc.)\n* Chronic pulmonary disorders, including chronic obstructive pulmonary disease that would limit ability to follow the protocol (investigator judgment) and obstructive sleep apnea syndrome; only subjects with mild or exercise-induced asthma on no medications or on beta-adrenergic agonists only will be allowed to enter the study (provided use of these agents is not required for 1 week before\n* Diagnosed gastrointestinal diseases, including inflammatory bowel diseases (e.g. Crohn's disease and ulcerative colitis), malabsorption syndromes (e.g. celiac disease), gastric ulcer (active); only subjects with gastro-esophageal reflux will be allowed to enter the study entry).\n* History of HIV infection or ongoing chronic infection (such as tuberculosis)\n* only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan (i.e., presence of metal in body, tattoos in head\u002Fneck region, claustrophobia etc.)",{"count":61,"type":21},"OBSERVATIONAL","Current study aims to characterize five highly interconnected physiological systems in patients undergoing cross-sex hormone therapy - namely glucose and lipid metabolism, energy balance, eating behavior, functional brain networks involved in the regulation of eating behavior and the cardiovascular system - to gain novel insights into the effects of sex hormones on the human body. Gathered information will help to identify pathophysiological mechanisms for the development of overeating\u002Fobesity, insulin resistance, and cardiovascular disease. Secondarily, the relationships between the gut and oral microbiomes and metabolomes and circulating bacterial signatures will be investigated in relation to the other pervasive physiological systems.\n\nCurrent study is an observational study. The decision if the patient's request for cross-sex hormone therapy can complied with (i.e., if cross-sex hormone therapy is medically indicated) is made prior to the first contact with the study center and with the outpatients clinic for Endocrinology at the University Hospital in Leipzig. Decision ifor treatment is made according to national and international guidelines. Treatment of study participants with testosterone and estradiol\u002Fantiandrogens is not affected by the study. During the course of the study no invasive interventions are being performed.",[89,30,90,91,92,93],"Transsexualism","Adiposity","Eating Behavior","Arterial Stiffness","Microangiopathy",[89,95,96,97,90,98],"Energy expenditure","Energy balance","Eating behavior","Cardiovascular disease","2025-11-27",{"date":72,"type":42},{"date":102,"type":42},"2021-05-05",{"date":104,"type":21},"2026-05",{"name":106,"class":49},"University of Leipzig",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":57,"sex":58,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":50},"100382032","transgender-men-non-binary-persons-and-testosterone-treatment-body-identity-clinic-100382032","NCT04254354","Transgender Men, Non-binary Persons and Testosterone Treatment BODY IDENTITY CLINIC","Masculinizing Testosterone Treatment and Effects on Preclinical Cardiovascular Disease, Muscle Strength and Power, Aggression, Physical Fitness and Respiratory Function in Transgender Men,Body Identity Clinic (BIC)","Inclusion Criteria:\n\nTransgender men\n\nExclusion Criteria:\n\nnone",{"count":115,"type":21},200,"The aim of this study is to investigate transgender men and non-binary persons before and during testosterone treatment. The study will focus on:\n\n* Cardiovascular status\n* Muscle strenght and power\n* Aggression and quality of life\n* Cardiac and respiratory function",[30],"2025-08-08",{"date":120,"type":42},"2025-08-13",{"date":122,"type":42},"2020-03-03",{"date":124,"type":21},"2044-01-01",{"name":126,"class":49},"Marianne Andersen",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":134,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":50},"100523287","prospective-imaging-assessment-of-perineo-pelvic-statics-evolution-after-sexual-reassignment-surgery-in-mtf-transgender-patient-by-peno-scrotal-inversion-vaginoplasty-technique-transpelv-100523287","NCT06093724","Prospective Imaging Assessment of Perineo-pelvic Static's Evolution After Sexual Reassignment Surgery in MtF Transgender Patient, by Peno-scrotal Inversion Vaginoplasty Technique (TRANSPELV)","TRANSPELV","Inclusion Criteria:\n\n* Patient over 18 years old\n* Patient admitted in urology ward at Limoges' University Hospital for MtF sexual reassignment surgery by vaginoplasty\n* Patient affiliated or benefitting from a social security system\n* Patient free, informed, written and signed consent\n\nExclusion Criteria:\n\n* Patient admitted for vulvoplasty surgery\n* Patient admitted for second vaginoplasty surgical gesture\n* Contraindication of realizing an MRI","MALE",{"count":136,"type":21},50,[24],"The research consists of adding to the usual MtF transgender patient undergoing vaginoplasty care course, static and dynamic perineo-pelvic MRI before, and at 6 and 24 months. The aim is to assess perineo-pelvic static's evolution, based on the appearance of a rectocele.",[30],[141],"MtF, transgender, vaginoplasty, penoscrotal inversion, MRI","2025-07-18",{"date":144,"type":42},"2025-07-22",{"date":146,"type":42},"2023-09-08",{"date":148,"type":21},"2026-07-15",{"name":150,"class":49},"University Hospital, Limoges",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":50},"100408293","pubertal-blockade-and-estradiol-effects-on-cardiometabolic-health-for-transitioning-youth-100408293","NCT04596592","Pubertal Blockade and Estradiol Effects on Cardiometabolic Health for Transitioning Youth","PUBERTY","Inclusion Criteria (transgender females):\n\n* Identify as a transgender female\n* Age 13-16 years at the time of enrollment\n* If on a gonadotropin releasing hormone analogue, \\> 6 months exposure\n* Plan to start estradiol clinically in \\\u003C 4 months\n\nInclusion Criteria (cisgender males and females):\n\n* Males and females ages 13-16 years\n\nExclusion Criteria:\n\n* Cognitive, psychiatric, or physical impairment resulting in inability to tolerate the study procedures\n* Antipsychotic medication use\n* Type 1 or 2 diabetes (by medical history)\n* Polycystic ovarian syndrome (PCOS for cisgender females)\n* Hypertension (resting BP ≥ 140\u002F90 mm\u002FHg)\n* Weight\\> 400 lbs\n* On oral progesterone medications (including oral progesterone or progestin, combined oral contraceptives or etonogestrel implant)\n* Pregnancy (for cisgender females)","13 Years","16 Years",{"count":161,"type":21},90,"To evaluate the effect of estradiol with or without a prior gonadotropin releasing hormone analogue on insulin sensitivity and vascular function in transgender females compared to cisgender controls.",[30,164,165],"Gender Dysphoria","Insulin Sensitivity","2025-06-05",{"date":168,"type":42},"2025-06-10",{"date":170,"type":42},"2021-02-15",{"date":172,"type":21},"2026-07-31",{"name":174,"class":49},"University of Colorado, Denver",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":134,"minAge":182,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":195,"locationsCount":50},"100399528","puberty-suppression-and-cardiometabolic-health-100399528","NCT04482374","Puberty Suppression and Cardiometabolic Health","Effects of Puberty and Pubertal Suppression on Insulin Sensitivity, Metabolic Rate and Vascular Health","Inclusion Criteria:\n\n* Identify as a transgender female or cisgender male\n* Age 9-14 years at the time of enrollment\n* Tanner Stage 2-3 baseline pubertal development\n* Plan to start gonadotropin releasing hormone analogue clinically in \\\u003C 2 months (for transgender females only)\n\nExclusion Criteria:\n\n* Cognitive, psychiatric, or physical impairment resulting in inability to tolerate the study procedures\n* Type 1 or 2 diabetes (by medical history)\n* On any medications that affect insulin sensitivity (e.g. metformin, antipsychotics)\n* Hypertension (resting BP ≥ 140\u002F90 mm\u002FHg)\n* Weight \\> 400 lbs\n* On estrogen- or progesterone-containing medications at baseline\n* \\>3 hours of moderate-to-vigorous physical activity on the 3DPAR at the screening visit","9 Years","14 Years",{"count":185,"type":21},30,"This observational study will evaluate the effect of puberty suppression on insulin sensitivity, metabolic rate and vascular health among transgender female youth at baseline and 6 months after initiation of a gondoatropin releasing hormone agonist compared to matched cisgender male controls.",[30,188,189,190],"Insulin Sensitivity\u002FResistance","Endothelial Dysfunction","Vascular Stiffness",{"date":168,"type":42},{"date":193,"type":42},"2020-08-10",{"date":172,"type":21},{"name":174,"class":49},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":57,"sex":58,"minAge":203,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":4},"100589636","lower-urinary-tract-symptoms-in-transmasculine-patients-undergoing-metoidioplasty-and-their-acceptability-of-pelvic-floor-muscle-training-assessed-by-a-pelvic-obstetric-and-gynaecological-physiotherapist-100589636","NCT06956989","Lower Urinary Tract Symptoms in Transmasculine Patients Undergoing Metoidioplasty and Their Acceptability of Pelvic Floor Muscle Training Assessed by a Pelvic, Obstetric and Gynaecological Physiotherapist","LUTS-POGP","Inclusion Criteria:\n\nHave capacity to consent.\n\nDiagnosis of gender dysphoria and have lived in a gender role that is congruent to their gender identity for minimum of 12 months.\n\nTransmasculine patients referred to CCGS for masculinising lower genital reconstructive surgery having received two signatures confirming suitability for reconstructive surgery.\n\nUndergoing metoidioplasty\u002Fphalloplasty.\n\nAge \\>17 years old.\n\nOn systemic testosterone therapy for more than 12 months.\n\nExclusion Criteria:\n\n* Age less than 18 years.\n\nNot undergoing metoidioplasty\u002Fphalloplasty.","17 Years",{"count":136,"type":21},"Lower urinary tract symptoms in transmasculine patients undergoing metoidioplasty and their acceptability of pelvic floor muscle training assessed by a Pelvic, Obstetric and Gynaecological Physiotherapist.\n\nStudy Design\n\nProspective observational pilot study\n\nStudy Participants\n\nTransmasculine patients undergoing metoidioplasty\n\nPlanned Sample Size\n\n50\n\nPlanned Study Period\n\n2025\u002F26\n\nObjectives\n\nUnderstand the acceptability of first-line pelvic floor muscle training (PFMT) treatment in transmasculine patients undergoing metoidioplasty\n\nBackground incidence of lower urinary tract symptoms (LUTS) in transmasculine patients undergoing surgery\n\nEndpoints\n\nAcceptability of PFMT questionnaire\n\nInternational Prostate Symptom Score (I-PSS) and International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form (ICIQ-UI SF) questionnaires and uroflowmetry",[207,30],"Lower Urinary Tract Symptoms","2025-04-25",{"date":210,"type":42},"2025-05-04",{"date":212,"type":21},"2025-08",{"date":214,"type":21},"2027-08",{"name":216,"class":49},"Chelsea and Westminster NHS Foundation Trust",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":134,"minAge":17,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":50},"100452304","feminizing-treatment-in-transgender-women-and-non-binary-persons-100452304","NCT05169762","Feminizing Treatment in Transgender Women and Non-binary Persons","Feminizing Treatment in Transgender Women and Non-binary Persons BODY IDENTITY CLINIC - ESTROGEN","BIC-Estrogen","Inclusion Criteria:\n\n* assigned male at birth and eligeble for gender affirming feminizing treatment\n\nExclusion Criteria:\n\nnone\n\n\\-",{"count":226,"type":21},100,"Cohort study in 100 transgender women treated with gender affirming hormone treatment. Follow up affter 1year, 3 years, 5 years and 10 years, Outcomes regarding cardiovascular effects of hormone treatment.",[30],[230,231,232],"gender affirming hormone treatment","estrogen","cardiovascular risk","2025-03-18",{"date":235,"type":42},"2025-03-21",{"date":237,"type":42},"2022-02-01",{"date":239,"type":21},"2035-09-01",{"name":241,"class":49},"Odense University Hospital",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":58,"minAge":17,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":251,"conditions":252,"keywords":256,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":50},"100565253","sexual-functioning-after-erection-prosthesis-placement-in-post-phalloplasty-transgender-persons-100565253","NCT06639776","Sexual Functioning After Erection Prosthesis Placement in Post Phalloplasty Transgender Persons","Sexual Functioning After Erection Prosthesis Placement in Post Phalloplasty Transgender Persons: a Retrospective Cohort","Inclusion Criteria:\n\n* Patient and partner age ≥ 18 years.\n* Transgender or gender non-conforming individuals diagnosed according to the DSM-5 diagnostic criteria for gender dysphoria.\n* Patients have undergone phalloplasty as a form of genital gender affirming surgery (any type of flap combination or technique is allowed).\n* Erection prosthesis placement ≥ 6 months after phalloplasty, performed at the Ghent University Hospital. Any type of prosthesis is allowed.\n* Patient has a functional erectile prosthesis at the time of the study. Number of erectile prosthesis is not relevant for inclusion.\n* Patient is Dutch, English or French speaking.\n* Voluntary signed and written consent by patient and their optional partner.\n\nExclusion Criteria:\n\n* Patient age \\< 18 years.\n* Cisgender patients treated with phalloplasty and\u002For erection prosthesis for various reasons.\n* The erection prosthesis has been explanted or the current prosthesis is nonfunctional at time of data assessment.\n* Erection prosthesis placement \\< 6 months before study start will be excluded.",{"count":250,"type":21},150,"This study aims to explore sexual satisfaction among transgender men and their partners following the placement of erectile prostheses after phalloplasty. While phalloplasty can create a neophallus, the lack of natural erectile tissue often necessitates the use of erectile aids, including internal prostheses. However, these prostheses, originally designed for cisgender men, face challenges when used in transgender patients, such as higher risks of complications, infections, and mechanical failures. Despite these issues, some studies report high patient satisfaction, though partner satisfaction rates are significantly lower. The study will use validated and non-validated questionnaires to assess satisfaction with various types of erectile prostheses, addressing the gap in understanding how these devices impact the sexual and relational functioning of both transgender men and their partners. These questionnaires will be provided to all included patients that are minimum 6 months after placement of an internal erection prosthesis and have a functional erection prosthesis in place",[30,253,254,164,255],"Erectile Dysfunction","Prosthesis Durability","Sexual Dysfunction",[257,258,259,260,261,262,263,264,265,266,267],"Gender dysphoria","Transgender","Phalloplasty","Erectile dysfunction","Sexual function","Erection prosthesis","Penile epithesis","Medical device","Penile splint","Genital reconstruction","Patient Reported Outcome Measures (PROMs)","2024-10-11",{"date":270,"type":42},"2024-10-15",{"date":272,"type":42},"2024-07-15",{"date":274,"type":21},"2025-07-31",{"name":276,"class":49},"University Hospital, Ghent",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":57,"sex":58,"minAge":17,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":287,"conditions":288,"keywords":289,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":50},"100565252","erectile-aid-use-in-post-phalloplasty-and-post-metoidioplasty-transgender-patients-100565252","NCT06639763","Erectile Aid Use in Post-phalloplasty and Post-metoidioplasty Transgender Patients","Erectile Aid Use in Post-phalloplasty and Post-metoidioplasty Transgender Patients: an Epidemiological Survey","AID","Inclusion Criteria:\n\n* Patient and partner age ≥ 18 years.\n* Transgender or gender non-conforming individuals (and their partners).\n* Patients have undergone phalloplasty or metoidioplasty as a form of genital gender affirming surgery.\n* ≥6 months after phalloplasty or metoidioplasty (any type of flap or technique is allowed).\n* Sexually active or has been sexually active since phalloplasty or metoidioplasty with a partner or main sexual partner.\n* Voluntarily agreed that the data may be used for an anonymized scientific study.\n\nExclusion Criteria:\n\n* Patient age \\< 18 years.\n* Cisgender patients treated with phalloplasty or metoidioplasty for various reasons.\n* \\<6 months after phalloplasty or metoidioplasty.\n* Not sexually active since phalloplasty\u002Fmetoidioplasty.\n* Patient and\u002For partner have no interest in penetrative sexual intercourse.",{"count":286,"type":21},1000,"This study seeks to explore the various methods used by transgender men for sexual intercourse following phalloplasty or metoidioplasty, focusing on their satisfaction with different erectile aids, as well as the satisfaction of their partners. Phalloplasty and metoidioplasty are gender-affirming surgeries that often require additional aids to achieve the desired sexual function, particularly for penetration. While internal erectile prostheses are common after phalloplasty, they come with high complication rates, leading some patients to opt for non-surgical aids. However, the effectiveness and comfort of these aids are not well-documented. This study aims to fill this gap by examining the types of aids transgender men use, how well these aids meet their sexual needs, and how satisfied both they and their partners are with the outcomes, providing much-needed insight for healthcare providers and patients alike.",[30,253,164,255],[257,258,259,290,260,261,266,291,292,267,262,263],"Metoidioplasty","Reconstructive urology","Erectile aid",{"date":270,"type":42},{"date":295,"type":42},"2024-07-06",{"date":297,"type":21},"2025-06-30",{"name":276,"class":49},{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":57,"sex":58,"minAge":17,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":320},"100507143","epithesis-versus-prosthesis-in-post-phalloplasty-transgender-patients-100507143","NCT05883553","Epithesis Versus Prosthesis in Post-phalloplasty Transgender Patients.","EROS","Inclusion Criteria:\n\n* Transgender or gender non-conforming individuals diagnosed according to the DSM-5 diagnostic criteria for gender dysphoria.\n* Patients have undergone phalloplasty as a form of genital gender affirming surgery.\n* ≥ 1 year after phalloplasty (any type of flap combination is allowed), performed at the Ghent University Hospital or Amsterdam UMC.\n* ≥ 3 months after coronaplasty and having reasonably pronounced coronal ridge, as defined by the surgeons' expert opinion (This criterion is only obligatory in the eptithesis group, not in the prosthesis group).\n* Anatomic penile length and girth as defined by the surgeons' expert opinion.\n* Absence of urethral stricture or other structural problem resulting in voiding dysfunction.\n* Normal uroflowmetry and post-void residue\n* Regain of at least minimal protective sensation up to the tip of the phallus as defined by Semmes-Weinstein monofilament testing.\n* Established (primary) sexual relationship with partner who is willing to take part in the study.\n* Both patient and partner have interest in penetrative sexual intercourse.\n* Patient is unable to penetrate the partner (anal or vaginal) adequately sexually without the aid of supportive measures (condom, taping, penile sleeve, penile epithesis or any other measure defined as supportive by the investigators).\n* Fit and eligible for erection prosthesis surgery, based on the surgeons' expert opinion.\n* No history of erection prosthesis surgery.\n* No interest in or fear of prosthesis surgery making this option obsolete (This criterion is only obligatory in the eptithesis group, not in the prosthesis group)\n* Treatment naïve in the use of the Elatortm or Erektortm epithesis.\n* Voluntarily signed written informed consent according to the rules of Good Clinical Practice (Declaration of Helsinki) and national regulations.\n\nExclusion Criteria:\n\n* Cisgender patients treated with phalloplasty various reasons.\n* Post-metoidioplasty patients (metoidioplasty as step-up to performed phalloplasty is allowed).\n* Absence of coronaplasty or coronaplasty performed \\\u003C 3 months ago or coronaplasty did not leave sufficiently pronounced coronal ridge as defined by the surgeons' expert opinion (This criterion is only obligatory in the epithesis group, not in the prosthesis group)\n* Penile dimensions are not anatomic (e.g. too small or too large).\n* Underlying LUTDs requiring further investigation and\u002For treatment.\n* Inadequate protective sensation in the penis.\n* No established (sexual) partner and\u002For partner is not willing to take part in the study.\n* Patient and\u002For partner have no interest in penetrative sexual intercourse.",{"count":307,"type":21},40,[24],"Transgender and gender diverse (TGD) individuals most often choose for phalloplasty as a means to create masculine external genitalia. The neophallus created in phalloplasty is usually insufficient for penetrative sexual intercourse due to the lack of erectile structures. Therefore, implantation of an internal erectile prosthesis or use of an external device or epithesis is required.\n\nInternal prostheses are the main method for attaining penile rigidity after phalloplasty, but they carry a high risk of complications. Previous research has shown that up to 22% of prostheses for cisgender men were explanted due to various reasons, including infection, erosion, and malfunction within 20 months. The lack of reliable and durable erectile devices leads to a large proportion of patients either choosing phalloplasty but never going for the placement of an erectile prosthesis or completely abandoning the idea of GGAS under the form of phalloplasty. Secondarily, TGD individuals may be concerned about complication rates and likely need for additional surgeries associated with penile implant surgery. Therefore, alternative options for transgender and gender non-conforming patients after phalloplasty are needed. These alternatives may be surgical or non-surgical.\n\nExternal penile epitheses or penile splints were originally designed for cisgender men with erectile dysfunction but have been used experimentally by post-phalloplasty transgender men. While there is no data on the usability and durability of penile epitheses in a TGD population, they may be a viable alternative to an internal penile prosthesis after phalloplasty. Penile lifters or splints, marketed as ElatorTM or ErektorTM, are commercially available and consist of two rigid rings connected by rigid metal rods. The biggest of two rings is placed around the base of the phallus, and the second ring is placed behind the coronal ridge. By connecting the rods to the ring at the base of the penis, tension and rigidity between the two rings is created, allowing the user to penetrate their partner and remove the device after intercourse.\n\nThe current study aims to extend the knowledge on these external devices by comparing them to the implantation of an internal penile prosthesis in post-phalloplasty transgender patients.",[30,253,254,164,255],[257,258,259,260,261,262,263,264,265,267,266,291],"2024-08-02",{"date":314,"type":42},"2024-08-05",{"date":316,"type":42},"2023-05-17",{"date":318,"type":21},"2025-12-31",{"name":276,"class":49},2,{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":57,"sex":16,"minAge":17,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":330,"briefSummary":331,"conditions":332,"keywords":335,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":320},"100549840","voice-outcome-of-glottoplasty-cricothyroid-approximation-thyroplasty-and-chondrolaryngoplasty-100549840","NCT06439290","Voice Outcome of Glottoplasty, Cricothyroid Approximation, Thyroplasty, and Chondrolaryngoplasty","PURPOSE 1:\n\nInclusion criteria for surgery participants:\n\n* Persons who will soon undergo surgery on the vocal folds and\u002For larynx (including glottoplasty, cricothyroid approximation, thyroplasty and\u002For thyroid chondroplasty) at UZ Gent\n* At least 18 years old\n* Sufficient command of the Dutch language for understanding the informed consent letter and completing Dutch questionnaires\n\nInclusion criteria for volunteers to provide speech samples:\n\n\\- Cisgender men or women\n\nInclusion criteria for volunteer listeners for the listening experiment:\n\n* Dutch-speaking\n* Self-reported normal hearing\n\nPURPOSE 2: same as above.\n\nPURPOSE 3:\n\nInclusion criteria for the healthy participants:\n\n* At least 18 years old\n* Sufficient command of the Dutch language to complete a Dutch questionnaire\n\nExclusion criteria for the healthy participants:\n\n\\- One or more contraindications for an MRI examination. These contraindications are checked using a questionnaire (safety checklist).\n\nInclusion criteria for the pre- and postoperative MRI participants:\n\n\\- Random selection of +- 10 participants of purpose 1.\n\nExclusion criteria for the pre- and postoperative MRI participants:\n\n\\- One or more contraindications for an MRI examination. These contraindications are checked using a questionnaire (safety checklist).","70 Years",{"count":329,"type":21},290,[24],"The purpose of this study is to measure the short- and long-term voice outcome and outcome predictors of glottoplasty, cricothyroid approximation, thyroplasty, and chondrolaryngoplasty using a prospective non-randomized controlled trial and a multidimensional voice assessment protocol. Secondly, a laryngeal magnetic resonance imaging protocol will be developed to measure pre- and postoperative anatomical factors and compare them with the acoustic changes.",[333,334,30,164],"Surgery","Larynx",[258,336,337,338],"Phonosurgery","Determinants","MRI","2024-05-30",{"date":341,"type":42},"2024-06-03",{"date":343,"type":42},"2024-04-10",{"date":345,"type":21},"2027-12",{"name":347,"class":49},"University Ghent"]